ATC Group: H01CA01 Gonadorelin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01CA01 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H01 Pituitary and hypothalamic hormones and analogues
3 H01C Hypothalamic hormones
4 H01CA Gonadotropin-releasing hormones
5 H01CA01 Gonadorelin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
NASAL - Nasal 1.2 mg

Active ingredients in H01CA01

Active Ingredient Description

Gonadorelin stimulates the synthesis of follicle stimulating hormone and luteinising hormone in the anterior lobe of the pituitary as well as their release.

Medicines in this ATC group

Austria (AT)

Canada (CA)

Estonia (EE)

France (FR)

Japan (JP)

Malta (MT)

Netherlands (NL)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.